Genomes and Genes

Species

Ashim K Mitra

Summary

Affiliation: University of Missouri-Kansas City
Country: USA

Publications

  1. Owiti A, Mitra A, Joseph M, Pal D. Strategic Pentablock Copolymer Nanomicellar Formulation for Paclitaxel Delivery System. AAPS PharmSciTech. 2018;: pubmed publisher
    ..Results confirmed that pentablock copolymer can generate drug-loaded nanomicelles with desirable sizes and zeta potential. These demonstrate potentiality of pentablock nanomicelles as carrier for anticancer delivery. ..
  2. request reprint
    Vadlapatla R, Vadlapudi A, Pal D, Mitra A. Role of membrane transporters and metabolizing enzymes in ocular drug delivery. Curr Drug Metab. 2014;15:680-93 pubmed
    ..Further, the significance of transporter- metabolism interplay in ophthalmic drug design and various ocular drug delivery strategies are also outlined. ..
  3. Yang X, Trinh H, Agrahari V, Sheng Y, Pal D, Mitra A. Nanoparticle-Based Topical Ophthalmic Gel Formulation for Sustained Release of Hydrocortisone Butyrate. AAPS PharmSciTech. 2016;17:294-306 pubmed publisher
    ..PLGA NP dispersed in thermosensitive gels can be considered as a promising drug delivery system for the treatment of anterior eye diseases. ..
  4. Patel M, Sheng Y, Mandava N, Pal D, Mitra A. Dipeptide prodrug approach to evade efflux pumps and CYP3A4 metabolism of lopinavir. Int J Pharm. 2014;476:99-107 pubmed publisher
    ..Results obtained from this study suggested that dipeptide prodrug approach is a viable option to elevate systemic levels of LPV following oral administration. ..
  5. Vaishya R, Mandal A, Patel S, Mitra A. Extended release microparticle-in-gel formulation of octreotide: Effect of polymer type on acylation of peptide during in vitro release. Int J Pharm. 2015;496:676-88 pubmed publisher
    ..Conversely, polymers having PLA and PGA blocks may not be appropriate for peptide delivery due to acylation and incomplete release. ..
  6. Vaishya R, Khurana V, Patel S, Mitra A. Long-term delivery of protein therapeutics. Expert Opin Drug Deliv. 2015;12:415-40 pubmed publisher
    ..A large number of protein molecules are under clinical trials, and hence, there is an urgent need to develop new methods to deliver these highly potent biologics. ..
  7. Sheng Y, Yang X, Pal D, Mitra A. Prodrug approach to improve absorption of prednisolone. Int J Pharm. 2015;487:242-9 pubmed publisher
    ..Results obtained from these studies clearly suggest that peptide transporter targeted prodrugs is a viable strategy to improve aqueous solubility and overcome P-gp mediated cellular efflux of prednisolone. ..
  8. Sheng Y, Yang X, Wang Z, Mitra A. Stereoisomeric Prodrugs to Improve Corneal Absorption of Prednisolone: Synthesis and In Vitro Evaluation. AAPS PharmSciTech. 2016;17:718-26 pubmed publisher
    ..Results obtained from this study clearly suggest that stereoisomeric prodrug approach is an effective strategy to overcome P-gp-mediated efflux and improve transcorneal permeability of prednisolone following topical administration. ..
  9. Mitra A, Agrahari V, Mandal A, Cholkar K, Natarajan C, Shah S, et al. Novel delivery approaches for cancer therapeutics. J Control Release. 2015;219:248-268 pubmed publisher
    ..Lowering multi-drug resistance and involving influx transportation in targeted drug delivery to cancer cells can also contribute significantly in the therapeutic interventions in cancer. ..

More Information

Publications26

  1. request reprint
    Ray A, Mandal A, Joseph M, Mitra A. Recent Patents on Nanoparticles and Nanoformulations for Cancer Therapy. Recent Pat Drug Deliv Formul. 2016;10:11-23 pubmed
    ..This manuscript will review different aspects of nanoparticles and recent research advances and patents for treatment of cancer. ..
  2. request reprint
    Ray A, Mandal A, Mitra A. Recent Patents in Pulmonary Delivery of Macromolecules. Recent Pat Drug Deliv Formul. 2015;9:225-36 pubmed
    ..The diseases targeted by these therapeutic molecules are varied including but not limited to different forms of cancer, respiratory diseases etc. ..
  3. Vaishya R, Mandal A, Gokulgandhi M, Patel S, Mitra A. Reversible hydrophobic ion-paring complex strategy to minimize acylation of octreotide during long-term delivery from PLGA microparticles. Int J Pharm. 2015;489:237-45 pubmed publisher
    ..Therefore, HIP complexation could be a viable strategy to minimize acylation of peptides and proteins during extended release from lactide and glycolide based polymers. ..
  4. Cholkar K, Trinh H, Pal D, Mitra A. Discovery of novel inhibitors for the treatment of glaucoma. Expert Opin Drug Discov. 2015;10:293-313 pubmed publisher
    ..In the near future, microRNA intervention may be considered as a potential therapeutic target. ..
  5. Patel S, Vaishya R, Yang X, Pal D, Mitra A. Novel thermosensitive pentablock copolymers for sustained delivery of proteins in the treatment of posterior segment diseases. Protein Pept Lett. 2014;21:1185-200 pubmed
    ..Owing to biodegradability, thermosensi- tivity, ease of handling and biocompatibility PBC hydrogels can be considered as promising biomaterial for sustained de- livery of protein therapeutics to the back of the eye. ..
  6. Cholkar K, Gilger B, Mitra A. Topical delivery of aqueous micellar resolvin E1 analog (RX-10045). Int J Pharm. 2016;498:326-34 pubmed publisher
    ..Topical aqueous formulations may be employed to treat posterior ocular diseases. Such micellar topical formulations may be more patient acceptable over invasive routes of administrations such as intravitreal injection/implants. ..
  7. Vadlapatla R, Pal D, Mitra A. Uptake and Permeability Studies to Delineate the Role of Efflux Transporters. Methods Mol Biol. 2016;1395:69-74 pubmed publisher
    ..This chapter presents a method of performing uptake and permeability studies, including the preparation of various buffers required for the study. ..
  8. request reprint
    Bisht R, Mandal A, Rupenthal I, Mitra A. Ex vivo investigation of ocular tissue distribution following intravitreal administration of connexin43 mimetic peptide using the microdialysis technique and LC-MS/MS. Drug Deliv Transl Res. 2016;6:763-770 pubmed
    ..This ex vivo model may therefore be a useful tool to investigate intravitreal kinetics and ocular disposition of therapeutic molecules after intravitreal injection. ..
  9. Mandal A, Pal D, Mitra A. Circumvention of P-gp and MRP2 mediated efflux of lopinavir by a histidine based dipeptide prodrug. Int J Pharm. 2016;512:49-60 pubmed publisher
    ..Histidine based dipeptide prodrug approach can be an alternative strategy to improve LPV absorption across poorly permeable intestinal barrier. ..
  10. Mandal A, Bisht R, Rupenthal I, Mitra A. Polymeric micelles for ocular drug delivery: From structural frameworks to recent preclinical studies. J Control Release. 2017;248:96-116 pubmed publisher
  11. Mandal A, Pal D, Agrahari V, Trinh H, Joseph M, Mitra A. Ocular delivery of proteins and peptides: Challenges and novel formulation approaches. Adv Drug Deliv Rev. 2018;126:67-95 pubmed publisher
    ..We will also describe the current state of proteins and peptides based ocular therapy and future therapeutic opportunities. ..
  12. request reprint
    Vadlapatla R, Vadlapudi A, Pal D, Mitra A. Mechanisms of drug resistance in cancer chemotherapy: coordinated role and regulation of efflux transporters and metabolizing enzymes. Curr Pharm Des. 2013;19:7126-40 pubmed
    ..The pharmacological role of PXR and advances in the development of PXR antagonists to overcome MDR are outlined. ..
  13. Agrahari V, Mandal A, Agrahari V, Trinh H, Joseph M, Ray A, et al. A comprehensive insight on ocular pharmacokinetics. Drug Deliv Transl Res. 2016;6:735-754 pubmed
    ..Moreover, several ocular pharmacokinetics animal models and relevant studies are reviewed and discussed in addition to the pharmacokinetics of various ocular formulations. ..
  14. Trinh H, Cholkar K, Joseph M, Yang X, Mitra A. Clear, Aqueous Topical Drop of Triamcinolone Acetonide. AAPS PharmSciTech. 2017;18:2466-2478 pubmed publisher
    ..Overall, these studies suggest that TA in NMF is safe and suitable for human topical ocular drop application. ..
  15. Agrahari V, Patel S, Dhall N, Aulgur Z, Thukral S, Yang X, et al. Nanoparticles in thermosensitive gel based composite nanosystem for ocular diseases. Drug Deliv Transl Res. 2018;8:422-435 pubmed publisher
    ..Based on the results, it is anticipated that long-term ocular delivery of macromolecules can be achieved through composite nanosystems. ..
  16. Khurana V, Kwatra D, Pal D, Mitra A. Molecular expression and functional activity of vitamin C specific transport system (SVCT2) in human breast cancer cells. Int J Pharm. 2014;474:14-24 pubmed publisher
    ..Also, MDA-MB231, T47D and ZR-75-1 cell lines can be utilized as a valuable in vitro model to investigate absorption and permeability of AA-conjugated chemotherapeutics. ..